| A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) (NCT07491458) | Rivus Pharmaceuticals, Inc. | 2026-02-13 |
| Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6 (NCT07170189) | Rivus Pharmaceuticals, Inc. | 2025-10-13 |
| Relative Bioavailability Study of HU6 (NCT06486558) | Rivus Pharmaceuticals, Inc. | 2024-07-24 |
| A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6 (NCT06325930) | Rivus Pharmaceuticals, Inc. | 2024-03-26 |
| Ph 2a Study of HU6 on Energy Metabolism, Muscle and Liver Substrate Metabolism, and Mitochondrial Function in Subjects Who Are Overweight or Obese With Type 2 Diabetes (NCT06104358) | Rivus Pharmaceuticals, Inc. | 2023-11-17 |
| Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis (NCT05979779) | Rivus Pharmaceuticals, Inc. | 2023-09-05 |
| Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF (NCT05284617) | Rivus Pharmaceuticals, Inc. | 2022-10-30 |
| Safety and Pharmacokinetics of HU6 (NCT05433506) | Rivus Pharmaceuticals, Inc. | 2022-09-15 |
| Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers (NCT04874233) | Rivus Pharmaceuticals, Inc. | 2021-04-19 |
| Multiple Ascending Dose Study of HU6 in High BMI Volunteers (NCT04709913) | Rivus Pharmaceuticals, Inc. | 2021-01-04 |
| Ascending Dose Study of HU6 in Healthy Volunteers (NCT04463017) | Rivus Pharmaceuticals, Inc. | 2020-08-12 |